CME Certificates will be issued digitally after Speaker Evaluations and Overall Surveys are completed. Surveys are accessible after logging in with the email address you submitted during registration. Surveys will be available online starting the day of the symposium. You must complete the process by May 26, 2025 in order to receive your certificate. Certificates will be available online until September 1, 2025 and are printable directly from the website.
The AAFP has reviewed 29th Annual Heart Failure 2025: An Update on Therapy and deemed it acceptable for up to 6.25 Live AAFP Prescribed credits. Term of Approval is from 05/03/25 to 05/03/25. Physicians should claim only the credit commensurate with the extent of their participation in the activity. AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 credit(s)™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.
The 29th Annual Heart Failure 2025: An Update on Therapy continues the tradition of providing a comprehensive update on the prevention, diagnosis, and management of heart failure. The program includes lectures presented by experts combined with an opportunity for interactive discussion with faculty. The extensive list of topics has been selected to provide high level and clinically relevant updates on the contemporary approach for the prevention and management of acute and chronic heart failure with the goal of improving clinicians’ knowledge and the care of patients with heart failure of various etiologies.
At the conclusion of this activity, participants should be able to:
The program has been designed to provide cardiologists, internists, primary care physicians, pharmacists, nurses and other healthcare providers with the necessary information to increase knowledge with the goal of improving the care of patients with HF.
Current estimates show 6.5 million Americans over the age of 20 have heart failure (HF) with 960,000 new cases diagnosed annually. HF is complex and multifaceted and is one of the most common causes of cardiovascular mortality and severe morbidity resulting in a higher rate of hospitalizations. Recently developed and approved drugs and devices for the management of heart failure of various etiologies offer a greater opportunity for improved outcome and need to be incorporated into the care of patients with these conditions. Recent data continues to show an important gap between published guideline recommendations for diagnosis and treatment of heart failure and practice (Journal of Clinical Medicine 2023; 12:1020) and demonstrate that life-saving drugs and devices are underutilized. Failure of proper guideline-directed medical and device therapy has been shown to confer a significant excess mortality (Clin. Cardiol. 2021; 44:1192–1198). Most patients with HF are managed by non-cardiologist health care providers and providers without training in advanced heart failure (Int. J Cardiol 2021; 343:63). Physicians’ education has been shown to result in a significant improvement in knowledge scales in HF care (PLoS One 2022 Feb 4;17(2): e0263523) and is of utmost importance.
This activity is in compliance with California Assembly Bills 1195 and 241 which requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. Cultural competency is defined as a set of integrated attitudes, knowledge, and skills that enables health care professionals or organizations to care effectively for patients from diverse cultures, groups, and communities. Linguistic competency is defined as the ability of a physician or surgeon to provide patients who do not speak English or who have limited ability to speak English, direct communication in the patient’s primary language. Cultural and linguistic competency was incorporated into the planning of this activity.